XML 26 R14.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Capital Transactions | 6 Months Ended
--- | ---
Jun. 30, 2017
Capital Transactions |
Capital Transactions | Capital Transactions Dividends On March 7, 2017, the Company announced a cash dividend of $0.10 per common share in the aggregate of $1.9 million, which was paid on April 3, 2017, to shareholders of record as of March 22, 2017. On May 10, 2017, the Company announced that its Board of Directors elected to suspend the payment of quarterly dividends. The Company's Board of Directors will periodically evaluate the Company’s dividend policy in the future. The declaration of future dividends is subject to the discretion of the Company’s Board of Directors and will depend upon various factors, including the Company’s earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by the Company's Board of Directors. Share Repurchase Program In November 2014, the Board of Directors authorized a $20.0 million share repurchase program beginning January 1, 2015. Such purchases may be made in the open market, through block trades, in privately negotiated transactions or otherwise. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors and the program may be discontinued or suspended at any time. At June 30, 2017, the remaining balance available for repurchases under the program was $13.4 million. There were no repurchases of common shares under the share repurchase program by the Company during the six months ended June 30, 2017 and 2016. Share-Based Compensation During the year ended December 31, 2012, the Company’s shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of the Company’s common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, the Company’s shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. The Company also maintains a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares. Stock Options The Company’s outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the six-month period ended June 30, 2017, is as follows (amounts in thousands, except per share information):
| Number of Shares |  | Weighted Average Exercise Price Per Share
Options outstanding at December 31, 2016 | 1,524 |  |  | $ | 12.41 |
Granted | 25 |  |  | 13.50 |
Forfeited or canceled | — |  |  | — |
Exercised | (9 | ) |  | 11.98 |
Options outstanding at June 30, 2017 | 1,540 |  |  | 12.34 |
During the six months ended June 30, 2017, the Company issued options to purchase 25,000 shares of common stock under the 2012 Stock Incentive Plan to a new member of the Company's Board of Directors. These options were issued with an exercise price of $13.50 per share and a grant date fair value of $4.94 per share, with expected life of five years, risk-free interest rate of 1.8 percent, and expected volatility of 39.8 percent. During the six months ended June 30, 2017, the Company modified vested options to purchase 131,000 shares of common stock for one individual (included in options outstanding above) to extend the expiration date for approximately one year. It is expected the options will terminate by June 30, 2018. This was a modification of the terms of an equity award, and accordingly, the Company treated this as an exchange of the original award for a new award. The Company recorded incremental compensation expense of approximately $0.1 million for the six months ended June 30, 2017, which was included in selling, general and administrative expense on the accompanying statements of operations. Share-based compensation expense from time-based stock options for the three-month periods ended June 30, 2017 and 2016, was approximately $0.3 million and $0.2 million, respectively. Share-based compensation expense from time-based stock options for the six-month periods ended June 30, 2017 and 2016, was approximately $0.4 million and $0.4 million, respectively. As of June 30, 2017 and December 31, 2016, the unrecognized share-based compensation expense related to the grants described above was $0.2 million and $0.3 million, respectively. As of June 30, 2017, the remaining compensation cost is expected to be recognized over the weighted-average period of approximately 0.6 years. At June 30, 2017, the aggregate intrinsic value of outstanding stock options to purchase 1,540,000 shares of common stock, exercisable stock options to purchase 1,409,000 shares of common stock and stock options to purchase 130,000 shares of common stock that are expected to vest was $2.2 million, $2.2 million and $0, respectively. At December 31, 2016, the aggregate intrinsic value of outstanding options to purchase 1,524,000 shares of common stock, the exercisable options to purchase 1,201,000 shares of common stock, and options to purchase 306,000 shares of common stock expected to vest was $4.2 million, $3.7 million and $0.4 million, respectively. For the six-month periods ended June 30, 2017 and 2016, the Company issued 9,000 and 25,000 shares of common stock upon the exercise of stock options at an average exercise price of $11.98 and $2.35 per share, respectively. The aggregate intrinsic values of options exercised during the six-month periods ended June 30, 2017 and 2016, was $7,000 and $0.2 million, respectively. For the six-month period ended June 30, 2017 and 2016, the Company recognized $0 and $0.1 million of tax benefits from the exercise of stock options during the period, respectively. Restricted Stock Units The Company’s outstanding restricted stock units ("RSUs"), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 48 months from the RSU grant date, as well as performance-based RSUs, which vest either upon achieving cumulative annual net sales growth targets over a rolling one-year period or upon achieving earnings-per-share targets over a rolling one-year period. RSUs granted to the Board of Directors contain a restrictive period pursuant to which the shares are not issued until two years after vesting. At June 30, 2017, and December 31, 2016, there were 65,000 and 69,000, respectively, vested RSUs that have been granted to the Board of Directors that have vested but remain subject to the two-year restriction period. RSU activity for the six-month period ended June 30, 2017, is as follows (amounts in thousands, except per share information):
| Number of Shares |  | Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding at December 31, 2016 | 838 |  |  | $ | 11.39 |
Granted | 256 |  |  | 12.69 |
Forfeited | (25 | ) |  | 12.37 |
Issued | (165 | ) |  | 12.16 |
Restricted Stock Units outstanding at June 30, 2017 | 904 |  |  | 11.68 |
During the six-month period ended June 30, 2017, the Company granted 256,000 RSUs under the 2012 Incentive Plan to the Company’s Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and net sales and operating income and earnings-per-share performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $12.69 per share and vest in annual installments over a three-year period from the grant date or according to the restrictions for the Board of Directors noted above. The net sales and operating income and earnings-per-share performance-based RSUs were issued with a weighted-average grant date fair value of $13.35 per share and vest upon achieving both (i) net sales and operating income targets over a three-year period from the grant date and (ii) earnings-per-share targets over a six-year period from the grant date. RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. Share-based compensation expense for RSUs for the three-month periods ended June 30, 2017 and 2016, was approximately $0.7 million and $0.5 million, respectively. Share-based compensation expense from RSUs for the six-month periods ended June 30, 2017 and 2016, was approximately $1.3 million and $1.1 million, respectively. As of June 30, 2017, and December 31, 2016, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.6 million and $2.0 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 1.2 years. The Company has not recognized any share-based compensation expense related to the net sales and earnings-per-share performance-based RSUs for the six-month periods ended June 30, 2017 and 2016. Should the Company attain all of the net sales metrics related to the net sales performance-based stock option grants, the Company would recognize up to $4.2 million of potential share-based compensation expense. The number of shares issued upon vesting of RSUs granted pursuant to the Company's share-based compensation plans is net of the minimum statutory withholding requirements that the Company pays on behalf of its employees, which was 20,000 shares for the six-month period ended June 30, 2017. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.

X
- References No definition available. + Details
Name: | natr_CapitalTransactionsDisclosureAbstract
Namespace Prefix: | natr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Entire disclosure of dividends and share based compensation of the reporting entity. + References No definition available. + Details
Name: | natr_DividendsAndShareBasedCompensationDisclosureTextBlock
Namespace Prefix: | natr_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration